Kamil Kośmider

Mr. Kamil Kośmider

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MMMarta Malczewska
Marta Malczewska
KKKamil Kośmider
Kamil Kośmider
KBKinga Anna Bednarz
Kinga Anna Bednarz
KOKatarzyna Ostapińska
Katarzyna Ostapińska
MLMonika Lejman
Monika Lejman
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
Acute lymphoblastic leukemia is the most common blood cancer in pediatric patients. There has been enormous progress in ALL treatment in recent years, which is reflected by the increase in the 5-year OS from 57% in the 1970s to up to 96% in the most recent studies. ALL treatment is based primarily on conventional methods, which include chemotherapy and radiotherapy. Their main weakness is severe toxicity, which prompts dose reduction, decreases the effectiveness of the treatment, and, in some cases, can lead to death. Currently, numerous modifications in treatment regimens are applied in order to limit toxicities emerging from conventional approaches and improve outcomes. Hematological treatment of pediatric patients is reaching for more novel treatment options, such as targeted treatment, CAR-T-cells therapy, and immunotherapy. These methods are currently used in conjunction with chemotherapy. Nevertheless, the swift progress in their development and increasing efficacity can lead to applying those novel therapies as standalone therapeutic options for pediatric ALL.

Verified
Journal Article
Open access
PDF file
KKKamil Kośmider
Kamil Kośmider
MKMaciej Kamieniak
Maciej Kamieniak
Stanisław CzuczwarStanisław Czuczwar
Stanisław Czuczwar
BMBarbara Marta Miziak
Barbara Marta Miziak
Epilepsy is a chronic disease of the central nervous system characterized by recurrent epileptic seizures. As a result of epileptic seizure or status epilepticus oxidants are excessively formed, which may be one of the causes of neuronal death. Given the role of oxidative stress in epileptogenesis, as well as the participation of this process in other neurological conditions, we decided to review the latest state of knowledge regarding the relationship between selected newer antiepileptic drugs (AEDs), also known as antiseizure drugs, and oxidative stress. The literature review indicates that drugs enhancing GABA-ergic transmission (e.g., vigabatrin, tiagabine, gabapentin, topiramate) or other antiepileptics (e.g., lamotrigine, levetiracetam) reduce neuronal oxidation markers. In particular, levetiracetam may produce ambiguous effects in this regard. However, when a GABA-enhancing drug was applied to the healthy tissue, it tended to increase oxidative stress markers in a dose-dependent manner. Studies on diazepam have shown that it exerts a neuroprotective effect in a “U-shaped” dose-dependent manner after excitotoxic or oxidative stress. Its lower concentrations are insufficient to protect against neuronal damage, while higher concentrations produce neurodegeneration. Therefore, a conclusion follows that newer AEDs, enhancing GABA-ergic neurotransmission, may act similarly to diazepam, causing neurodegeneration and oxidative stress when used in high doses.

Verified
Journal Article
Open access
PDF file
MKMaciej Kamieniak
Maciej Kamieniak
KKKamil Kośmider
Kamil Kośmider
BMBarbara Marta Miziak
Barbara Marta Miziak
Stanisław CzuczwarStanisław Czuczwar
Stanisław Czuczwar
Oxidative stress develops when there is an excess of oxidants leading to molecular and cellular damage. Seizure activity leads to oxidative stress and the resulting increased lipid peroxidation. Generally, antiseizure medications reduce oxidative stress, although the data on levetiracetam are ambiguous. Exogenous antioxidants (vitamin E, resveratrol, hesperidin, and curcumin) have been documented to exert an anticonvulsant effect in animal models of seizures and some recent clinical data point to curcumin as an affective adjuvant for the therapy of pediatric intractable epilepsy. Melatonin is an antioxidant with an ability to attenuate seizure activity induced by various convulsants in rodents. Its clinical effectiveness has been also confirmed in a number of clinical studies. Experimental studies point to a possibility that endogenous melatonin may possess proconvulsive activity. Moreover, some scarce clinical data seem to express this view; however, a limited number of patients were included. The anticonvulsant activity of exogenous melatonin may involve GABA-mediated inhibition, while endogenous melatonin may act as a proconvulsant due to a decrease in the brain dopaminergic transmission. Antioxidants, including melatonin, may be considered as adjuvants in the therapy of epilepsy and melatonin, in addition, in patients with epilepsy suffering from sleep disorders.

Verified
Journal Article
Open access
PDF file
KKKamil Kośmider
Kamil Kośmider
KKKatarzyna Karska
Katarzyna Karska
AKAgata Kozakiewicz
Agata Kozakiewicz
MLMonika Lejman
Monika Lejman
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
Acute lymphoblastic leukemia (ALL) is the most common malignancy among children. Despite the enormous progress in ALL therapy, resulting in achieving a 5-year survival rate of up to 90%, the ambitious goal of reaching a 100% survival rate is still being pursued. A typical ALL treatment includes three phases: remission induction and consolidation and maintenance, preceded by a prednisone prephase. Poor prednisone response (PPR) is defined as the presence of ≥1.0 × 109 blasts/L in the peripheral blood on day eight of therapy and results in significantly frequent relapses and worse outcomes. Hence, identifying risk factors of steroid resistance and finding methods of overcoming that resistance may significantly improve patients’ outcomes. A mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK-ERK) pathway seems to be a particularly attractive target, as its activation leads to steroid resistance via a phosphorylating Bcl-2-interacting mediator of cell death (BIM), which is crucial in the steroid-induced cell death. Several mutations causing activation of MAPK-ERK were discovered, notably the interleukin-7 receptor (IL-7R) pathway mutations in T-cell ALL and rat sarcoma virus (Ras) pathway mutations in precursor B-cell ALL. MAPK-ERK pathway inhibitors were demonstrated to enhance the results of dexamethasone therapy in preclinical ALL studies. This report summarizes steroids’ mechanism of action, resistance to treatment, and prospects of steroids therapy in pediatric ALL.

18 November 2021 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
AFAleksandra Filipiuk
Aleksandra Filipiuk
AKAgata Kozakiewicz
Agata Kozakiewicz
KKKamil Kośmider
Kamil Kośmider
MLMonika Lejman
Monika Lejman
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
Introduction and objective: Nijmegen breakage syndrome (NBS) is a rare chromosomal instability disorder. The majority of patients carry founder mutation in the NBN gene (c.657_661del5). Characteristic features of the NBS include progressive microcephaly, dysmorphic facial features,...

30 September 2021 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
KKKamil Kośmider
Kamil Kośmider
AKAgata Kozakiewicz
Agata Kozakiewicz
AFAleksandra Filipiuk
Aleksandra Filipiuk
DSDorota Sławińska
Dorota Sławińska
MLMonika Lejman
Monika Lejman
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
A 13-year-old girl with neurofibromastosis (NF1) was admitted to the Department of Paediatric Haematology, Oncology and Transplantology due to progressive vision loss in September 2018. The patient was diagnosed with optic nerve gliomas and chemotherapy was initiated. During the treatment,...